STOCK TITAN

[Form 4] Aligos Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Aligos Therapeutics (NASDAQ: ALGS) submitted a routine Form 4 disclosing a standard equity compensation grant to director Heather Preston. On 06/25/2025, Preston received 5,860 non-qualified stock options with an exercise price of $7.63 per share, matching the prevailing market price. The award vests 100 percent on the earlier of the first anniversary of the grant or immediately before the 2026 annual shareholder meeting, conditional on continued board service. No common shares were purchased or sold, and Preston’s beneficial ownership now reflects only the newly issued derivative securities.

Aligos Therapeutics (NASDAQ: ALGS) ha presentato un modulo Form 4 ordinario che comunica una consueta assegnazione di compensi azionari al membro del consiglio Heather Preston. In data 25/06/2025, Preston ha ricevuto 5.860 opzioni su azioni non qualificate con un prezzo di esercizio di 7,63 $ per azione, corrispondente al prezzo di mercato vigente. Il premio matura completamente al primo anniversario della concessione o immediatamente prima dell'assemblea annuale degli azionisti del 2026, a condizione che Preston continui il servizio nel consiglio. Non sono state acquistate o vendute azioni ordinarie e la proprietà effettiva di Preston riflette ora solo i titoli derivati appena emessi.

Aligos Therapeutics (NASDAQ: ALGS) presentó un Formulario 4 rutinario que revela una concesión estándar de compensación en acciones a la directora Heather Preston. El 25/06/2025, Preston recibió 5,860 opciones sobre acciones no calificadas con un precio de ejercicio de $7.63 por acción, igualando el precio de mercado vigente. La concesión se consolida en un 100% en el primero de estos dos eventos: el primer aniversario de la concesión o inmediatamente antes de la reunión anual de accionistas de 2026, condicionado a la continuidad en el servicio del consejo. No se compraron ni vendieron acciones ordinarias, y la propiedad beneficiaria de Preston ahora refleja únicamente los valores derivados recién emitidos.

Aligos Therapeutics (NASDAQ: ALGS)는 이사 Heather Preston에게 표준 주식 보상 부여를 공개하는 정기 Form 4를 제출했습니다. 2025년 6월 25일, Preston은 주당 행사 가격이 $7.635,860개의 비자격 주식 옵션을 받았으며, 이는 당시 시장 가격과 일치합니다. 이 보상은 부여일로부터 1주년 또는 2026년 연례 주주총회 직전 중 빠른 시점에 100% 베스팅되며, 이사회 서비스 지속 조건이 붙어 있습니다. 보통주는 매매되지 않았고, Preston의 실질 소유권은 새로 발행된 파생 증권만 반영합니다.

Aligos Therapeutics (NASDAQ: ALGS) a déposé un formulaire 4 habituel révélant une attribution standard de rémunération en actions à la directrice Heather Preston. Le 25/06/2025, Preston a reçu 5 860 options d'achat d'actions non qualifiées avec un prix d'exercice de 7,63 $ par action, correspondant au prix du marché en vigueur. La récompense devient pleinement acquise au premier anniversaire de l'attribution ou immédiatement avant l'assemblée annuelle des actionnaires de 2026, selon la première éventualité, conditionnée à la poursuite du service au conseil. Aucune action ordinaire n'a été achetée ou vendue, et la propriété bénéficiaire de Preston reflète désormais uniquement les titres dérivés nouvellement émis.

Aligos Therapeutics (NASDAQ: ALGS) reichte ein routinemäßiges Formular 4 ein, das eine übliche Aktienvergütung an die Direktorin Heather Preston offenlegt. Am 25.06.2025 erhielt Preston 5.860 nicht qualifizierte Aktienoptionen mit einem Ausübungspreis von 7,63 $ je Aktie, entsprechend dem aktuellen Marktpreis. Die Zuteilung wird zu 100 % fällig am früheren der beiden Termine: dem ersten Jahrestag der Gewährung oder unmittelbar vor der Hauptversammlung 2026, vorausgesetzt, die Vorstandsmitgliedschaft wird fortgesetzt. Es wurden keine Stammaktien gekauft oder verkauft, und Prestons wirtschaftliches Eigentum spiegelt nun ausschließlich die neu ausgegebenen derivativen Wertpapiere wider.

Positive
  • None.
Negative
  • None.

Aligos Therapeutics (NASDAQ: ALGS) ha presentato un modulo Form 4 ordinario che comunica una consueta assegnazione di compensi azionari al membro del consiglio Heather Preston. In data 25/06/2025, Preston ha ricevuto 5.860 opzioni su azioni non qualificate con un prezzo di esercizio di 7,63 $ per azione, corrispondente al prezzo di mercato vigente. Il premio matura completamente al primo anniversario della concessione o immediatamente prima dell'assemblea annuale degli azionisti del 2026, a condizione che Preston continui il servizio nel consiglio. Non sono state acquistate o vendute azioni ordinarie e la proprietà effettiva di Preston riflette ora solo i titoli derivati appena emessi.

Aligos Therapeutics (NASDAQ: ALGS) presentó un Formulario 4 rutinario que revela una concesión estándar de compensación en acciones a la directora Heather Preston. El 25/06/2025, Preston recibió 5,860 opciones sobre acciones no calificadas con un precio de ejercicio de $7.63 por acción, igualando el precio de mercado vigente. La concesión se consolida en un 100% en el primero de estos dos eventos: el primer aniversario de la concesión o inmediatamente antes de la reunión anual de accionistas de 2026, condicionado a la continuidad en el servicio del consejo. No se compraron ni vendieron acciones ordinarias, y la propiedad beneficiaria de Preston ahora refleja únicamente los valores derivados recién emitidos.

Aligos Therapeutics (NASDAQ: ALGS)는 이사 Heather Preston에게 표준 주식 보상 부여를 공개하는 정기 Form 4를 제출했습니다. 2025년 6월 25일, Preston은 주당 행사 가격이 $7.635,860개의 비자격 주식 옵션을 받았으며, 이는 당시 시장 가격과 일치합니다. 이 보상은 부여일로부터 1주년 또는 2026년 연례 주주총회 직전 중 빠른 시점에 100% 베스팅되며, 이사회 서비스 지속 조건이 붙어 있습니다. 보통주는 매매되지 않았고, Preston의 실질 소유권은 새로 발행된 파생 증권만 반영합니다.

Aligos Therapeutics (NASDAQ: ALGS) a déposé un formulaire 4 habituel révélant une attribution standard de rémunération en actions à la directrice Heather Preston. Le 25/06/2025, Preston a reçu 5 860 options d'achat d'actions non qualifiées avec un prix d'exercice de 7,63 $ par action, correspondant au prix du marché en vigueur. La récompense devient pleinement acquise au premier anniversaire de l'attribution ou immédiatement avant l'assemblée annuelle des actionnaires de 2026, selon la première éventualité, conditionnée à la poursuite du service au conseil. Aucune action ordinaire n'a été achetée ou vendue, et la propriété bénéficiaire de Preston reflète désormais uniquement les titres dérivés nouvellement émis.

Aligos Therapeutics (NASDAQ: ALGS) reichte ein routinemäßiges Formular 4 ein, das eine übliche Aktienvergütung an die Direktorin Heather Preston offenlegt. Am 25.06.2025 erhielt Preston 5.860 nicht qualifizierte Aktienoptionen mit einem Ausübungspreis von 7,63 $ je Aktie, entsprechend dem aktuellen Marktpreis. Die Zuteilung wird zu 100 % fällig am früheren der beiden Termine: dem ersten Jahrestag der Gewährung oder unmittelbar vor der Hauptversammlung 2026, vorausgesetzt, die Vorstandsmitgliedschaft wird fortgesetzt. Es wurden keine Stammaktien gekauft oder verkauft, und Prestons wirtschaftliches Eigentum spiegelt nun ausschließlich die neu ausgegebenen derivativen Wertpapiere wider.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Preston Heather

(Last) (First) (Middle)
C/O ALIGOS THERAPEUTICS, INC.
1 CORPORATE DRIVE, 2ND FLOOR

(Street)
SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Aligos Therapeutics, Inc. [ ALGS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/25/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $7.63 06/25/2025 A 5,860 (1) 06/25/2035 Common Stock 5,860 $0 5,860 D
Explanation of Responses:
1. The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2026 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date.
/s/ Lesley Ann Calhoun, as attorney-in fact for Heather Preston 06/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many stock options did Heather Preston receive according to the Form 4?

The filing reports a grant of 5,860 stock options with an exercise price of $7.63.

Were any ALGS common shares bought or sold in this insider filing?

No. The Form 4 records only an option grant; there were no share purchases or sales.
Aligos Therapeutics, Inc.

NASDAQ:ALGS

ALGS Rankings

ALGS Latest News

ALGS Latest SEC Filings

ALGS Stock Data

43.90M
4.76M
11.58%
34.03%
20.13%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO